Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Saturday's Exclusive Content
3 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch. First Published: 4/9/2026. 
Key Points
- Dividend Aristocrats including Amcor, Chevron, and AbbVie can provide reliable income streams that can help offset persistent inflation.
- Each of those three companies offers a yield above 3% combined with decades of consistent dividend growth, signaling strong financial stability.
- These stocks also provide exposure to defensive sectors like packaging, energy, and health care, which tend to perform well during periods of elevated inflation.
- Special Report: Elon Musk already made me a “wealthy man”
The calendar says it’s spring, but investors can’t be blamed for feeling like it’s Groundhog Day: the economic challenges affecting portfolios are still with us. Just after a ceasefire between the United States and Iran was announced—providing a meaningful market tailwind—investors are getting fresh inflation readings that appear to be moving in the wrong direction. The Personal Consumption Expenditures (PCE) index and the Consumer Price Index (CPI) for March are both out this week, and both reports are expected to show inflation creeping higher.
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776.
One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. Read Porter Stansberry's full breakdown and protect your wealth now
Worse, those readings don't yet reflect the impact of higher oil prices, which tend to be inflationary. Whether this is a short-lived headwind or a longer-term problem remains to be seen. There are multiple layers to the inflation story. Even if oil prices fall and the economy accelerates, stronger demand can be inflationary. Interest rates matter, too: the Federal Reserve has paused cuts, and a vocal minority expects rates to move higher next. The only near certainty is that inflation is unlikely to drop to the Fed’s 2% target anytime soon. One practical move for investors now is to buy dividend stocks yielding over 3%. Even if share prices don’t rise much, growing yields can help returns outpace inflation. Rather than chasing yield, a better approach is to seek companies with a consistent record of paying and increasing dividends. Below are three Dividend Aristocrats that have raised payouts for at least 25 consecutive years. Amcor Offers High Yield With Defensive DemandAmcor (NYSE: AMCR) is a global packaging company with market leadership across food and beverage, pharmaceutical, and personal care categories. Its products are typically in steady demand, which can help in periods when companies look to cut input costs. That said, Amcor’s stock hasn’t excited investors over the past year—AMCR is roughly flat over 12 months. But its dividend appears secure. The company has increased its payout for 27 consecutive years, a streak that includes dividend history from its 2019 Bemis acquisition. As of April 9, the yield was 6.3%, with an annual payout of $2.60 per share. Amcor faces cost pressure from tariffs and higher oil prices. Trading at roughly 27x earnings, AMCR looks pricey relative to its history and the broader market. Still, the dividend is intact, and analysts have a consensus one-year price target of $52, which would be a gain of more than 20% in addition to the generous yield. Chevron Combines Energy Exposure With Dividend StrengthEnergy stocks have been volatile since the Iran conflict intensified in late February. Chevron (NYSE: CVX) has been one of the beneficiaries: year to date, CVX is up almost 30%. If oil stays elevated, investors will be glad to own CVX. Even if oil prices retreat, Chevron is a best-in-class integrated oil major positioned to increase output in the U.S. and, more recently, in Venezuela. The company also has significant exposure to the growing liquefied natural gas market and strategic investments in renewable energy. The recent run-up has made CVX somewhat expensive on a short-term basis. But Chevron’s long-term track record matters: in 2025 the company generated $20.2 billion in free cash flow and returned a record $27 billion to shareholders through dividends and buybacks. Chevron’s dividend yields about 3.6%, paying $7.12 per share annually. The company has increased its dividend for 38 consecutive years. AbbVie Delivers Reliable Growth and Income in Health CareHealth care isn’t the obvious inflation hedge, but people keep filling prescriptions when prices rise. That resilience makes AbbVie (NYSE: ABBV) worth considering. In 2025 AbbVie reported record revenue of $61.2 billion, with immunology sales up 14% driven by flagship drugs Skyrizi and Rinvoq. Those products have largely offset the revenue lost when Humira went off patent. That performance matters for the dividend. Many worried Humira’s patent expiration would force a payout cut, but ABBV has continued raising its dividend for 52 consecutive years. The yield is about 3.3%, equal to $6.92 per share annually. AbbVie is more a long-term hold than a trading stock—an investment to let compounding work over time. |
Post a Comment
Post a Comment